VINORELBINE- vinorelbine tartrate injection, solution
Sagent Pharmaceuticals


  • Severe myelosuppression resulting in serious infection, septic shock, hospitalization and death can occur [see Warnings and Precautions (5.1)].
  • Decrease the dose or withhold vinorelbine in accord with recommended dose modifications [see Dosage and Administration (2.2)].


Vinorelbine Injection is indicated:

  • In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
  • As a single agent for the treatment of patients with metastatic NSCLC


2.1 Recommended Dosage

In Combination with Cisplatin 100 mg/m 2

  • The recommended dosage of Vinorelbine Injection is 25 mg/m2 administered as an intravenous injection or infusion over 6 to 10 minutes on Days 1, 8, 15 and 22 of a 28-day cycle in combination with cisplatin 100 mg/m2 on Day 1 only of each 28-day cycle.

In Combination with Cisplatin 120 mg/m 2

  • The recommended dosage of Vinorelbine Injection is 30 mg/m2 administered as an intravenous injection or infusion over 6 to 10 minutes once a week in combination with cisplatin 120 mg/m2 on Days 1 and 29, then every 6 weeks.

Single Agent

  • The recommended dosage of Vinorelbine Injection is 30 mg/m2 administered intravenously over 6 to 10 minutes once a week.

2.2 Dosage Modifications


Hold or decrease the dose of Vinorelbine Injection in patients with decreased neutrophil counts according to the following schema [see Warnings and Precautions (5.1)]:

Neutrophils on Day of Treatment (cells/mm 3 ) Percentage of Starting Dose of Vinorelbine Injection
≥ 1,500 100%
1,000 to 1,499 50%
< 1,000 Do not administer Vinorelbine Injection.Repeat neutrophil count in one week.If three consecutive weekly doses are held becauseneutrophil count is < 1,000 cells/mm3 , discontinue Vinorelbine Injection
Note: For patients who experience fever and/or sepsis while neutrophil count is < 1,500 cells/mm3 or had 2 consecutive weekly doses held due to neutropenia, subsequent doses of Vinorelbine Injection should be:
> 1,500 75%
1,000 to 1,499 37.5%
< 1,000 Do not administer Vinorelbine Injection. Repeat neutrophil count in one week.

Hepatic Impairment/Toxicity

Reduce Vinorelbine Injection dose in patients with elevated serum total bilirubin concentration according to the following schema [see Warnings and Precautions (5.2) and Use in Specific Populations (8.6)]:

Serum Total Bilirubin Concentration (mg/dl) Percentage of Starting Dose of Vinorelbine Injection
≤ 2.0 100%
2.1 to 3.0 50%
> 3.0 25%

Concurrent Myelosuppression and Hepatic Impairment/Toxicity

In patients with both myelosuppression and hepatic impairment/toxicity, administer the lower of the doses based on the corresponding starting dose of Vinorelbine Injection determined from the above schemas.

Neurologic Toxicity

Discontinue Vinorelbine Injection for Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or higher peripheral neuropathy or autonomic neuropathy causing constipation [see Warnings and Precautions (5.5)].

2.3 Preparation and Administration


Dilute Vinorelbine Injection in an intravenous bag to a concentration between 0.5 mg/mL and 2 mg/mL. Use one of the following recommended solutions for dilution:

  • 5% Dextrose Injection, USP
  • 0.9% Sodium Chloride Injection, USP
  • 0.45% Sodium Chloride Injection, USP
  • 5% Dextrose and 0.45% Sodium Chloride Injection, USP
  • Ringer’s Injection, USP
  • Lactated Ringer’s Injection, USP

Stability and Storage Conditions of Diluted Solutions

Diluted Vinorelbine Injection may be used for up to 24 hours under normal room light when stored in polyvinyl chloride bags at 5° to 30°C (41° to 86°F).


Administer diluted Vinorelbine Injection over 6 to 10 minutes into the side port of a free-flowing intravenous line followed by flushing with at least 75 to 125 mL of one of the solutions.

Vinorelbine Injection must only be administered intravenously. It is extremely important that the intravenous needle or catheter be properly positioned before any Vinorelbine Injection is injected.

Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration whenever solution and container permit. If particulate matter is seen, Vinorelbine Injection should not be administered.

Management of Suspected Extravasation

  • If Vinorelbine Injection leakage into surrounding tissue occurs or is suspected, immediately stop administration of Vinorelbine Injection and initiate appropriate management measures in accordance with institutional policies [see Warnings and Precautions (5.4)].

2.4 Procedures for Proper Handling and Disposal

Vinorelbine Injection is a cytotoxic drug. Follow applicable special handling and disposal procedures1.

Exercise caution in handling and preparing the solution of Vinorelbine Injection. The use of gloves is recommended. If the solution of Vinorelbine Injection contacts the skin or mucosa, immediately wash the skin or mucosa thoroughly with soap and water.

Avoid contamination of the eye with Vinorelbine Injection. If exposure occurs, flush the eyes with water immediately and thoroughly.

Discard unused portion.


Vinorelbine Injection, USP: 1 mL (10 mg per 1 mL) and 5 mL (50 mg per 5 mL) clear colorless to pale yellow solution in single-dose vial.

All resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2023. All Rights Reserved.